Detalles de la búsqueda
1.
T cell responses to COVID-19 infection and vaccination in patients with multiple sclerosis receiving disease-modifying therapy.
Mult Scler;
29(6): 648-656, 2023 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-36440826
2.
Ocrelizumab treatment for relapsing-remitting multiple sclerosis after a suboptimal response to previous disease-modifying therapy: A nonrandomized controlled trial.
Mult Scler;
28(5): 790-800, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-34382875
3.
Development and Validation of the FSIQ-RMS: A New Patient-Reported Questionnaire to Assess Symptoms and Impacts of Fatigue in Relapsing Multiple Sclerosis.
Value Health;
22(4): 453-466, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30975397
4.
Expression of GM-CSF in T Cells Is Increased in Multiple Sclerosis and Suppressed by IFN-ß Therapy.
J Immunol;
194(11): 5085-93, 2015 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-25917097
5.
A retrospective claims analysis of fatigue in patients with multiple sclerosis on disease-modifying therapy.
Mult Scler Relat Disord;
78: 104917, 2023 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-37597349
6.
Multiple sclerosis: relationship between locus of control and quality of life in persons with low versus high disability.
Health Psychol Behav Med;
10(1): 316-334, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35309243
7.
Side effects that occurred early in people with multiple sclerosis during the first year of treatment with cladribine tablets: a plain language summary.
Neurodegener Dis Manag;
12(1): 1-7, 2022 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35019731
8.
Relapses in people with multiple sclerosis treated with cladribine tablets followed for up to 5 years: a plain language summary.
Neurodegener Dis Manag;
12(6): 303-310, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36017797
9.
Physician Compensation in the United States - Through the Lens of the MS Neurologist.
Mult Scler Relat Disord;
50: 102847, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33618121
10.
Challenges in multiple sclerosis care: Results from an international mixed-methods study.
Mult Scler Relat Disord;
50: 102854, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33690086
11.
Integrated Lymphopenia Analysis in Younger and Older Patients With Multiple Sclerosis Treated With Cladribine Tablets.
Front Immunol;
12: 763433, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-35003076
12.
Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.
Mult Scler J Exp Transl Clin;
7(3): 20552173211024298, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-34345436
13.
Early MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Mult Scler J Exp Transl Clin;
7(1): 2055217321990852, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-33717501
14.
N-acetyl cysteine administration affects cerebral blood flow as measured by arterial spin labeling MRI in patients with multiple sclerosis.
Heliyon;
7(7): e07615, 2021 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-34377857
15.
Subgroup analysis of clinical and MRI outcomes in participants with a first clinical demyelinating event at risk of multiple sclerosis in the ORACLE-MS study.
Mult Scler Relat Disord;
49: 102695, 2021 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-33578191
16.
The Relationship Between Multiple Sclerosis Symptom Severity Measures and Performance on Driving Variability Metrics in a Virtual Reality Simulator.
Am J Phys Med Rehabil;
99(4): 278-284, 2020 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-31764226
17.
The Development of Cladribine Tablets for the Treatment of Multiple Sclerosis: A Comprehensive Review.
Drugs;
80(18): 1901-1928, 2020 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-33247831
18.
N-acetyl Cysteine Administration Is Associated With Increased Cerebral Glucose Metabolism in Patients With Multiple Sclerosis: An Exploratory Study.
Front Neurol;
11: 88, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32117038
19.
When metals compete: a case of copper-deficiency myeloneuropathy and anemia.
Nat Clin Pract Neurol;
5(2): 106-11, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-19194390
20.
Cladribine tablets added to IFN-ß in active relapsing MS: The ONWARD study.
Neurol Neuroimmunol Neuroinflamm;
5(5): e477, 2018 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-30027104